Search Results
Dec 19, 2025, 14:38 ET Sunlight.com Survey: 1 in 7 Americans Plan To Use GLP-1s in 2026
As GLP-1s grow in popularity, more Americans are rethinking weight loss in the new yearKIRKLAND, Wash, Dec. 19, 2025 /PRNewswire/ -- A new survey from Sunlight.com finds that interest in GLP-1 medications
More news about: Sunlight
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.2 If approved, CagriSema would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment."The FDA submission
More news about: NOVO NORDISK INC.
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.2 If approved, CagriSema would become the first injectable GLP-1 receptor agonist and amylin analogue combination treatment. "The FDA submission of
More news about: NOVO NORDISK INC.
Dec 18, 2025, 07:53 ET CHIPOTLE UNVEILS ITS FIRST-EVER HIGH PROTEIN MENU FEATURING A NEW SNACK-READY HIGH PROTEIN CUP
calories) – A GLP-1 friendly bowl featuring Adobo Chicken, light brown rice, black beans, fajita veggies, roasted chili-corn salsa, fresh tomato salsa and romaine lettuceHigh Protein-Low Calorie Salad (36g protein, 10g fiber, 470 calories) – A GLP-1 friendly salad
More news about: Chipotle Mexican Grill, Inc.
Dec 18, 2025, 06:45 ET Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human
More news about: Eli Lilly and Company
Dec 17, 2025, 19:00 ET Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
development and commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose
More news about: Innovent Biologics
Dec 17, 2025, 13:19 ET BIOCARE NUTRITION LAUNCHES AT SELECT HY-VEE LOCATIONS
needs—whether consumers are new to GLP-1 therapy or simply looking for smarter functional nutrition.About Biocare NutritionBiocare Nutrition is a forward-thinking wellness brand focused on supporting individuals using GLP-1 medications and others seeking targeted
More news about: Robard Corporation
Dec 17, 2025, 09:15 ET Concerns with Traditional PBM and Transparent Models Accelerates Demand for the First True Fiduciary PBM
business model.Mayer, K. (2025, June 6). How much of employers' annual claims do GLP-1 drugs account for? SHRM.Media Inquiries:Karla Jo HelmsJOTO PR™727-777-4629Jotopr.com
More news about: US-Rx
Dec 17, 2025, 09:05 ET Shed Launches Three New Wellness Solutions: Microdose GLP-1, NAD+ and Glutathione for Energy, Clarity, and Healthy Aging
people feel better every day, in ways that last."Simple Tools for Real-Life WellnessMicrodose GLP-1Shed's microdose GLP-1 program offers low-dose versions of Semaglutide and Tirzepatide to support metabolism, energy, and focus—without the intense
More news about: Shed
Dec 16, 2025, 17:05 ET The Next Chapter in Obesity Therapeutics: Vial's INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy
from leading institutions such as Johns Hopkins, GMU, and Dartmouth University respectively shared their insights on challenges with current GLP-1 treatments as well as the potential benefits of INHBE siRNA therapies like Vial'sINHBE siRNAs are designed to
More news about: Vial
Dec 16, 2025, 11:53 ET Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Post-hoc analysis suggests rilparencel demonstrated treatment effects incremental to standard-of-care medications including SGLT2 inhibitors and GLP-1 receptor agonists."The Phase 2 REGEN-007 full results recently presented at ASN Kidney Week further strengthen the body of evidence supporting
More news about: Equity Insider
Dec 16, 2025, 10:00 ET Abarca Unveils Better Balance and Better Access: Two Bold Moves to Redefine Pharmacy Benefit Management for a New Era of Care
Better Balance is Abarca's new clinical program designed to restore cardiometabolic homeostasis across diabetes, obesity, hypertension, and GLP-1 therapy management. By integrating Welldoc's AI-powered digital health platform with Abarca's real-time clinical decision-making tools, we deliver
More news about: Abarca
Dec 16, 2025, 09:30 ET DARK SWEET CHERRY NAMED 2026 'FLAVOR OF THE YEAR' IN ANNUAL FOOD AND BEVERAGE TRENDS REPORT
flavors will grow to complement the growing trend of low-no-alcohol beverages.Snackable Meals: exploring how the growth of GLP-1 medications is leading to development of bite-sized treats and satisfying meals in smaller snackable portions.Fermented Flavors:
More news about: T. Hasegawa USA, Inc.
Dec 16, 2025, 09:22 ET Le-Vel's XERA Launch Goes Live, Redefining Age-Defying Transformation with Proprietary Exosome Technology
Experience, the advanced THRIVE ELITE Experience, and its newest innovation, myGLP—a holistic dietary system designed to support the body's natural GLP-1 production for healthy metabolism, digestion, mental clarity, and appetite control. With more than 10 million Customer and Brand Promoter accounts,
More news about: Le-Vel Brands
Dec 16, 2025, 08:57 ET Orangetheory Fitness Reignites Annual Transformation Challenge as Americans Prioritize Strength and Longevity
approval on social media (14%). And while GLP-1 use continues to rise culturally, 54% of GLP-1 users say medications alone are not enough for lasting transformation, citing
More news about: Orangetheory Fitness
Dec 16, 2025, 08:00 ET Cradle AI-powered protein engineering platform serving six of top 25 pharma leaders
partnered with Novo Nordisk to accelerate development of therapeutic candidates that could become the next generation of GLP-1 smash hits like Wegovy and Ozempic."2025 was an exceptional year for Cradle. We made AI a powerful, everyday tool for scientists building
More news about: Cradle
Dec 16, 2025, 00:35 ET Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025
in conjunction with the 9th Japan-Korea-Taiwan Symposium on Obesity.The animal study explored CBL-514 in combination with a dual GLP-1/GIP receptor agonist (tirzepatide), evaluating body weight and adipose tissue–related parameters in animal models.NEW
More news about: Caliway
Dec 15, 2025, 11:00 ET FlyteHealth Featured for U.S. Medicare ACCESS Program, Marking a Major Step Forward in Scalable Cardio-Kidney Metabolic Care
Medication Management: A disciplined, evidence-based methodology for personalized care plans and medication optimization—anti-hypertensives, GLP-1s, non-GLP-1s, hyperlipidemia and diabetes management—guided by patient response, acuity, and emerging best practices.This dual-engine model is
More news about: FlyteHealth
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, an oral GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).For
More news about: Ascletis Pharma Inc.
Dec 12, 2025, 06:12 ET Weekly Recap: 11 Health Press Releases You Need to See
AlabamaThe Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly's oral GLP-1, orforglipron. The company plans to create 3,450 manufacturing and construction jobs at Lilly's ninth U.S. manufacturing site announced since 2020.
More news about: PR Newswire
Dec 11, 2025, 19:00 ET Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
Company (Lilly) for the development and commercialization of mazdutide, a dual GCG /GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing
More news about: Innovent Biologics
Dec 11, 2025, 16:40 ET InstaMed® Pharmaceuticals Announces Month-Over-Month Hypergrowth, Successful Study, and Expands Its Patented Peptide Delivery Platform Nationwide
advancing several new product initiatives, including prescription-based formulations for erectile dysfunction, metabolic and hormone optimization, and GLP therapeutics. These developments position the company for significant expansion into regulated pharmaceutical channels.International interest
More news about: InstaMed® Pharmaceuticals
Dec 11, 2025, 10:17 ET Platform Technologies Drive $211B Surge in Precision Cancer Treatment
wholly-owned selective degrader portfolio with its Selective CBP degrader entering non-GLP toxicology studies in Q4 2025 and progressing toward IND-readiness in 2026 for potential treatment of EP300-mutant cancers and ER+ breast cancer."Momentum
More news about: Equity Insider
Dec 11, 2025, 09:42 ET Nitinotes annuncia che è stato trattato il primo paziente nello studio clinico cardine EASE™ che valuta il sistema di sutura automatizzato EndoZip™ per ESG
automatizzato, con un singolo operatore, con una tecnica di sutura manuale ampiamente adottata. Esiste un divario terapeutico significativo tra la terapia con GLP-1, che presenta alti tassi di abbandono, e la chirurgia bariatrica invasiva. L'ESG offre un'alternativa importante e prove cliniche generate in modo rigoroso
More news about: Nitinotes
Dec 11, 2025, 07:00 ET Everflow Drives $4.3 Billion in High-Value Partner Revenue, Delivering Essential Solutions for Modern Affiliate Programs
across key sectors, including financial services with clients like Freedom Financial, Pacific Debt, and Thor Precious Metals; the surging GLP-1 and health and wellness space, with clients like
More news about: Everflow